32.41
-0.61(-1.85%)
Currency In USD
Address
825 Industrial Road
San Carlos, CA 94070
United States of America
Phone
650 837 0111
Website
Sector
Healthcare
Industry
Biotechnology
Employees
414
First IPO Date
June 12, 2020
| Name | Title | Pay | Year Born |
| Mr. Grant E. Pickering M.B.A. | Co-Founder, Chief Executive Officer & Director | 1.4M | 1968 |
| Mr. Harp Dhaliwal M.B.A. | Chief Technical Operations Officer | 146,484 | 1974 |
| Mr. James Wassil M.B.A., M.S. | Executive Vice President & Chief Operating Officer | 564,809 | 1969 |
| Mr. Paul W. Sauer M.B.A. | Senior Vice President of Process Development & Manufacturing | 608,956 | 1962 |
| Mr. Mikhail Eydelman J.D. | Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary | 813,774 | 1981 |
| Mr. Andrew L. Guggenhime M.B.A. | President & Chief Financial Officer | 987,799 | 1968 |
| Ms. Whitney Jones | Chief People Officer | 0 | N/A |
| Sam Iki | Senior Vice President of Project Management | 0 | N/A |
| Ms. Janet Graesser | Senior Vice President of Corporate Communications & Investor Relations | 0 | N/A |
| Dr. Jeff Fairman Ph.D. | Co-Founder & Vice President of Research | 0 | 1965 |
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.